Kantonsspital St.Gallen
login

The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading

Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Roessle & Gerhard Huber

abstract

Background
Aim was to analyze the expression of different cancer testis antigens (CTA) and to assess its prognostic value in salivary gland carcinomas.

Methods
Patients with salivary gland carcinomas diagnosed 1994 to 2010 were included. Baseline characteristics, pathohistological, clinical, and outcome data were assessed. Tissue microarrays were constructed and immunohistochemistry for different CTA (NY-ESO1, NY-BR1, MAGE A1, MAGE A3, MAGE A4, MAGE C1/CT7, and MAGE C2/CT10) was performed. CTA expression was assessed and statistically correlated with pathological and outcome data.

Results
Expression rates of CTA in salivary gland tumors ranged from 0% to 40%. MAGE A4 expression was associated with a lower tumor grade tumor grading ( = .017), and a favorable recurrence-free ( = .003), disease-specific ( = .046) and overall survival ( = .028).

Conclusions
MAGE A4 is a highly significant prognostic marker in salivary gland carcinoma; its expression is associated with low-grade histology, a low rate of distant metastasis and a favorable survival.

Level of Evidence
4.
   
citation Vital D, Ikenberg K, Moch H, Roessle M, Huber G. The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading. Laryngoscope Investig Otolaryngol 2018; 3:182-190.
   
type journal paper/review (English)
date of publishing 19-04-2018
journal title Laryngoscope Investig Otolaryngol (3/3)
ISSN print 2378-8038
pages 182-190
PubMed 30062133
DOI 10.1002/lio2.160